List view / Grid view
An assay is an analytical procedure in laboratory medicine, pharmacology and molecular biology for measuring the activity of a target entity.
A new fibre-optic method lets researchers monitor amyloid plaque buildup in living, freely moving mice – offering a minimally invasive way to track Alzheimer’s disease progression and test potential therapies.
6 October 2025 | By
As regulators move to phase out primate testing, NHP-derived iPSC cardiomyocytes are emerging as a scalable, ethical and scientifically robust alternative - offering drug developers a clear path to faster, more predictive, and more responsible innovation.
Early planning for potency CQAs, comparability and evolving global regulations can set advanced therapies on the fastest path to approval. Dr Christian Schneider shares how to prepare from the start to accelerate development without compromising the evidence regulators expect.
Multiomics, AI and liquid biopsies are giving researchers real-time insight into tumour biology and enabling more personalised cancer therapies. Find out how these technologies are advancing biomarker discovery, improving patient stratification, and guiding the design of new treatments.
Zasocitinib is a highly selective, investigational TYK2 inhibitor developed to target immune-mediated diseases with fewer off-target effects than traditional JAK inhibitors. This article explores its mechanism, selectivity data and clinical progress.
For decades, molecular glues have been stumbled upon rather than designed. A new scientific approach is now changing that – expanding what is considered druggable.
A new oral immunotherapy could change how peanut allergy is treated, targeting the gut to retrain the immune system and reduce the risk of life-threatening reactions. INP20’s nanoparticle technology promises a safer, more precise approach that could replace lifelong avoidance with lasting tolerance.
Every new CAR-T needs a new detection tool – until now. Anti-linker antibodies could change how researchers develop and track these therapies.
From gene therapy to Long Covid, better assays are helping researchers move promising drug candidates from early studies into clinical trials. Dr Alexandre Lucas explains the technologies, challenges and innovations driving this progress.
With few antiviral options available to immunocompromised patients, a new generation of therapies - like AIC468 - is aiming to change that.
Researchers at the University of Birmingham have developed a single-cell technique to track boron inside live tumour cells – making Boron Neutron Capture Therapy more effective in treating head and neck cancers.
Researchers have developed the first high-throughput tool to rapidly profile RNA modifications – a breakthrough that could lead to more precise treatments for cancer and antibiotic-resistant infections.
By combining human tissue models with explainable AI, researchers can analyse complex patient data to identify which treatments work best for which patients. First applied to inflammatory bowel disease, this approach could improve clinical trial success rates across many diseases.
From precision proteomics to AI-powered immune profiling, next-generation laboratory technologies are changing how new therapies are discovered and developed. Here are four innovations set to shape the lab of the future - and the future of drug discovery.
Researchers at Mount Sinai have identified three antibodies that target mpox and prevent severe disease in vivo. The work positions A35-specific antibodies as candidates for therapeutic development.
